Citadel Advisors’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $138K | Buy |
68,314
+40,074
| +142% | +$90.1K | ﹤0.01% | 11751 |
|
|
2025
Q4 | $46K | Sell |
28,240
-6,033
| -18% | -$8.72K | ﹤0.01% | 12068 |
|
|
2025
Q3 | $36.3K | Buy |
+34,273
| New | +$38.4K | ﹤0.01% | 12329 |
|
|
2025
Q1 | – | Sell |
-145,802
| Closed | -$145K | – | 15598 |
|
|
2024
Q4 | $125K | Buy |
+145,802
| New | +$205K | ﹤0.01% | 11126 |
|
|
2024
Q3 | – | Sell |
-1,576
| Closed | -$2.74K | – | 15284 |
|
|
2024
Q2 | $2.54K | Sell |
1,576
-3,386
| -68% | -$6.84K | ﹤0.01% | 13673 |
|
|
2024
Q1 | $11.4K | Buy |
+4,962
| New | +$11.5K | ﹤0.01% | 13416 |
|
|
2023
Q3 | – | Sell |
-121
| Closed | -$458 | – | 15140 |
|
|
2023
Q2 | $499 | Buy |
+121
| New | +$475 | ﹤0.01% | 14099 |
|
|
2022
Q2 | – | Sell |
-1,263
| Closed | -$12.1K | – | 14135 |
|
|
2022
Q1 | $24K | Sell |
1,263
-917
| -42% | -$14.4K | ﹤0.01% | 13195 |
|
|
2021
Q4 | $39K | Buy |
2,180
+444
| +26% | +$13.3K | ﹤0.01% | 13384 |
|
|
2021
Q3 | $64K | Sell |
1,736
-13,414
| -89% | -$595K | ﹤0.01% | 13223 |
|
|
2021
Q2 | $901K | Buy |
15,150
+12,558
| +484% | +$761K | ﹤0.01% | 8630 |
|
|
2021
Q1 | $174K | Sell |
2,592
-1,755
| -40% | -$137K | ﹤0.01% | 11882 |
|
|
2020
Q4 | $263K | Buy |
4,347
+573
| +15% | +$39.1K | ﹤0.01% | 9295 |
|
|
2020
Q3 | $298K | Buy |
3,774
+574
| +18% | +$45.8K | ﹤0.01% | 8144 |
|
|
2020
Q2 | $200K | Sell |
3,200
-32,860
| -91% | -$1.91M | ﹤0.01% | 8525 |
|
|
2020
Q1 | $1.91M | Buy |
36,060
+30,279
| +524% | +$3M | ﹤0.01% | 4213 |
|
|
2019
Q4 | $700K | Buy |
5,781
+2,000
| +53% | +$288K | ﹤0.01% | 6242 |
|
|
2019
Q3 | $686K | Sell |
3,781
-838
| -18% | -$118K | ﹤0.01% | 6222 |
|
|
2019
Q2 | $600K | Sell |
4,619
-255
| -5% | -$45.7K | ﹤0.01% | 6540 |
|
|
2019
Q1 | $1.19M | Sell |
4,874
-4,574
| -48% | -$1.21M | ﹤0.01% | 5285 |
|
|
2018
Q4 | $1.8M | Sell |
9,448
-30,351
| -76% | -$7.4M | ﹤0.01% | 4312 |
|
|
2018
Q3 | $13.1M | Buy |
39,799
+24,808
| +165% | +$7.6M | 0.01% | 1808 |
|
|
2018
Q2 | $4.68M | Sell |
14,991
-28,286
| -65% | -$8.64M | ﹤0.01% | 2870 |
|
|
2018
Q1 | $10.5M | Buy |
43,277
+41,466
| +2,290% | +$11.6M | 0.01% | 1682 |
|
|
2017
Q4 | $547K | Buy |
1,811
+1,284
| +244% | +$357K | ﹤0.01% | 5514 |
|
|
2017
Q3 | $139K | Buy |
+527
| New | +$152K | ﹤0.01% | 6909 |
|
|
2017
Q2 | – | Sell |
-51,763
| Closed | -$13M | – | 8083 |
|
|
2017
Q1 | $18.6M | Buy |
51,763
+23,024
| +80% | +$7.13M | 0.02% | 1011 |
|
|
2016
Q4 | $8.29M | Sell |
28,739
-22,285
| -44% | -$6.91M | 0.01% | 1518 |
|
|
2016
Q3 | $17.4M | Buy |
51,024
+29,410
| +136% | +$10.7M | 0.02% | 950 |
|
|
2016
Q2 | $9.19M | Sell |
21,614
-1,868
| -8% | -$770K | 0.01% | 1316 |
|
|
2016
Q1 | $7.51M | Buy |
23,482
+19,927
| +561% | +$6.8M | 0.01% | 1419 |
|
|
2015
Q4 | $1.84M | Sell |
3,555
-1,071
| -23% | -$395K | ﹤0.01% | 2832 |
|
|
2015
Q3 | $1.36M | Buy |
4,626
+878
| +23% | +$312K | ﹤0.01% | 3410 |
|
|
2015
Q2 | $1.47M | Sell |
3,748
-4,028
| -52% | -$1.42M | ﹤0.01% | 3441 |
|
|
2015
Q1 | $2.35M | Buy |
7,776
+7,565
| +3,585% | +$1.85M | ﹤0.01% | 2870 |
|
|
2014
Q4 | $47K | Sell |
211
-644
| -75% | -$133K | ﹤0.01% | 7245 |
|
|
2014
Q3 | $198K | Buy |
855
+776
| +982% | +$195K | ﹤0.01% | 5736 |
|
|
2014
Q2 | $17K | Sell |
79
-10,089
| -99% | -$2.25M | ﹤0.01% | 7399 |
|
|
2014
Q1 | $3.21M | Buy |
+10,168
| New | +$3.24M | ﹤0.01% | 2156 |
|
Other funds holding TXMD
RCMNY
CC
SCM
VCM
TC
ACM
Citadel Advisors's TXMD Position: Q1 2026 in Review
Citadel Advisors increased its TherapeuticsMD (TXMD) stake by 142% in Q1 2026, buying an estimated $90.1K and bringing the position to 68,314 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #11751.
Citadel Advisors first reported a position in TXMD in Q1 2014 and has held it in 39 quarters since. The position peaked at $18.6M in Q1 2017. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.
- Citadel Advisors held 68,314 shares of TherapeuticsMD worth $138K as of Q1 2026.
- Citadel Advisors bought 40,074 TherapeuticsMD shares in Q1 2026, an estimated $90.1K.
- TherapeuticsMD made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11751 holding.
- Citadel Advisors first reported a position in TherapeuticsMD in Q1 2014 and has held it in 39 quarters since.
- Citadel Advisors's TherapeuticsMD position peaked at $18.6M in Q1 2017.
- 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.